Sandoz Gets Approval For US Pegfilgrastim
Becomes First To Offer Both Long- And Short-Acting Biosimilars
Sandoz has finally received a much-awaited FDA approval for its pegfilgrastim biosimilar, Ziextenzo, which will be launched in the US “as soon as possible this year.”
